Catapres
In brief
- Catapres can be obtained from pharmacies; it is officially prescription‑only in nearly all jurisdictions, but availability varies and some pharmacies may supply it without a prescription—check local regulations and practice.
- Catapres (clonidine) is used for essential hypertension and, as extended‑release formulations (Kapvay), for ADHD; it is a centrally acting alpha‑2 adrenergic agonist that reduces sympathetic outflow to lower blood pressure and can modulate attention/arousal pathways.
- Usual doses: for adult hypertension immediate‑release tablets often start 0.1 mg twice daily and are titrated (typical maximum up to ~2.4 mg/day); ADHD (extended‑release Kapvay) often starts 0.1 mg at bedtime and may be increased weekly up to ~0.4 mg/day; transdermal patches are dosed as 0.1–0.3 mg per 24 h equivalents.
- Forms of administration: oral tablets (immediate‑release and extended‑release), transdermal patches (Catapres‑TTS), and injectable formulations for specialist/epidural use.
- Onset time: oral tablets usually begin to lower blood pressure within about 30–60 minutes (peak effects in a few hours); transdermal patches release drug more slowly with effects developing over hours to days.
- Duration of action: immediate‑release oral doses generally last several hours (commonly 6–12 h); extended‑release preparations and transdermal patches provide more sustained 24‑hour coverage depending on formulation.
- Alcohol warning: avoid excessive alcohol—alcohol can increase sedation and dizziness and may worsen hypotension when taken with clonidine.
- The most common side effect is dry mouth (xerostomia); other frequent effects include drowsiness, dizziness, constipation and possible bradycardia or orthostatic hypotension.
- Would you like to try catapres without a prescription?
Basic Catapres Information
- INN (International Nonproprietary Name): Clonidine
- Brand Names Available In Australia: Catapres (tablets 0.1 mg, 0.2 mg, 0.3 mg); Catapres-TTS (transdermal patches)
- ATC Code: C02AC01
- Forms & Dosages: Tablet 0.1 mg, 0.2 mg, 0.3 mg; Extended-release tablet 0.1 mg, 0.17 mg; Transdermal patch 0.1–0.3 mg/24hr equivalent; Injection 100 mcg/mL
- Manufacturers In Australia: not specified
- Registration Status In Australia: not specified
- OTC / Rx Classification: Prescription-only (Rx)
Critical Warnings, Restrictions And Patient Protection (Australia)
Safety-First Summary For Patients And Carers
Clonidine (INN) is a prescription-only medicine and must only be started after clinician review.
Do not stop clonidine suddenly because abrupt withdrawal can cause rebound hypertension and other withdrawal effects.
Typical starting regimens for hypertension include 0.1 mg twice daily with stepwise titration; maximum typical total doses up to approximately 2.4 mg/day are reported in clinical practice.
At point of supply, advise patients to monitor blood pressure and heart rate regularly while on clonidine.
Avoid alcohol and other sedatives while taking clonidine because of increased drowsiness and dizziness risk.
Keep clonidine out of reach of children and store it as directed on the label.
- Pharmacist Dispensing Checklist: Confirm current blood pressure and heart rate.
- Confirm pregnancy and breastfeeding status before supply.
- Ask about concomitant central nervous system depressants (opioids, benzodiazepines, sedating antihistamines).
- Confirm recent renal function tests or known renal impairment.
Documentation & Consent (Australian Context)
Record the counselling discussion in the patient’s clinical notes at the time of supply.
For telehealth prescriptions, ensure the e-prescription and the counselling record are retained in the patient file.
Document advice given about monitoring, driving, and the need to avoid abrupt cessation.
High-Risk Actions (Legal/Occupational)
- Advise not to drive until tolerability is established due to drowsiness and dizziness.
- Warn against operating heavy machinery or working at heights until effects on alertness and blood pressure are known.
- Document advice for safety-critical occupations and notify the prescriber if workplace restrictions apply.
High-Risk Groups (Elderly, Pregnancy, Chronic Illness)
Elderly patients have a higher risk of orthostatic hypotension and bradycardia and should start at lower doses with slow titration.
Renal impairment prolongs clonidine elimination; half-life may extend up to about 41 hours, so dose-reduction and longer dosing intervals are advised.
Clonidine crosses the placenta and appears in breastmilk; avoid use in pregnancy and breastfeeding unless a specialist advises otherwise and risks versus benefits have been discussed with the obstetric team.
Use caution in patients with hepatic disease and in those with cardiac conduction disorders.
Absolute contraindications include known hypersensitivity to clonidine and severe AV block (second- or third-degree) without a pacemaker.
Interaction With Activities (Driving, Workplace Safety Under Australian Law)
Patients must not drive or operate machinery until they know how clonidine affects their alertness and blood pressure.
Document safety advice given for people in safety-sensitive jobs and consider workplace disclosure when required.
Q&A — “Can I Drive After Taking It In Australia?”
Q: Can I drive after taking clonidine?
A: Not until you know how it affects you—drowsiness, dizziness and orthostatic hypotension are common; if impaired, do not drive and inform your employer if you have a safety-sensitive role.
Usage Basics
INN, Brand Names Available In Australia
INN: Clonidine.
Brand names available that are listed for Australia include Catapres tablets (0.1–0.3 mg) and Catapres-TTS transdermal patches.
Extended-release products used internationally include Kapvay and Nexiclon XR; Kapvay is specifically used for ADHD as an extended‑release formulation.
International synonyms that may appear on imported generics include Clonidina and Clonidin.
Legal Classification (TGA-Approved, PBS-Listed)
Clonidine is prescription-only in nearly all jurisdictions and should be prescribed by an authorised clinician.
Check the Australian Register Of Therapeutic Goods (ARTG) for current TGA entries and registered indications for each marketed clonidine product.
PBS subsidy status differs by formulation and indication; clinicians should confirm eligibility at prescribing and patients should check with the dispensing pharmacist about PBS criteria and co-payment details.
- Brands Vs Forms
- Catapres — Tablets 0.1/0.2/0.3 mg; Catapres-TTS — Transdermal patch; Kapvay — Extended‑release tablet 0.1 mg (ADHD).
| Product | Form | Typical Strength |
|---|---|---|
| Catapres | Tablet | 0.1–0.3 mg |
| Catapres-TTS | Transdermal Patch | 0.1–0.3 mg/24 hr eq. |
| Duraclon | Injection | 100 mcg/mL |
Dosing Guide
Standard Regimens (PBS Reference Dosing)
For essential hypertension, a common starting regimen is 0.1 mg twice daily by mouth with stepwise upward titration to effect.
Maximum typical total doses reported in clinical practice reach up to approximately 2.4 mg per day, depending on clinical response and tolerability.
For ADHD, extended‑release clonidine (Kapvay) is started at 0.1 mg at bedtime and increased by 0.1 mg at weekly intervals with a usual maximum around 0.4 mg per day in children where indicated.
Adjustments For Comorbidities
In elderly patients, start at the lower end of the dose range and increase slowly while monitoring for orthostatic hypotension and bradycardia.
In renal impairment reduce dose and extend dosing intervals because elimination is prolonged and half-life can be markedly increased.
Use caution and close monitoring in hepatic impairment and in patients with underlying cardiac conduction disease.
Q&A — “What If I Miss A Dose?”
Q: Missed dose guidance?
A: Take the missed dose as soon as you remember unless it is near the time for the next dose; do not double the dose to make up.
If using transdermal patches, replace them according to the manufacturer’s schedule and instructions; do not cut or alter patches.
- Titration Checklist: Start low, review BP/HR within 1–2 weeks, increase in small increments only if tolerated.
- Monitor blood pressure standing and sitting, and review for sedation or mood changes during titration.
Interaction Chart
Food And Drinks (Alcohol, Caffeine, Australian Diet Context)
Alcohol and other central nervous system depressants increase the sedative effect of clonidine and should be avoided or used with caution.
Caffeine does not have a direct pharmacokinetic interaction but may mask sedative effects and affect perceived alertness.
Advise patients about over‑the‑counter sleep aids, herbal products or indigenous remedies that can cause sedation when combined with clonidine.
Common Drug Conflicts
Clonidine can produce additive hypotension and bradycardia when combined with beta‑blockers, calcium‑channel blockers, ACE inhibitors, ARBs, diuretics and other antihypertensives.
Tricyclic antidepressants and MAO inhibitors can alter cardiovascular responses to clonidine; monitor closely if combined.
Concomitant use with other sedating medicines (opioids, benzodiazepines, sedating antihistamines) increases risk of profound sedation.
| Interacting Drug | Risk | Management |
|---|---|---|
| Beta‑blockers | Additive bradycardia/hypotension | Monitor HR/BP; adjust doses as required |
| ACE inhibitors / ARBs | Increased hypotension | Monitor BP closely during initiation and titration |
| Benzodiazepines / Opioids | Increased sedation; respiratory depression risk | Avoid combinations where possible; counsel on sedation |
User Reports & Trends (Australian Patient Feedback)
Common themes on Australian patient review platforms include dry mouth, drowsiness, dizziness and mixed reports on effectiveness for blood pressure control.
Some patients report skin irritation with Catapres‑TTS patches and note adherence difficulties due to sedation.
Price sensitivity and preference for PBS‑subsidised generics are common, and rural patients describe access delays and reliance on community pharmacists for monitoring.
- Top 5 Reported Issues: dry mouth, drowsiness/fatigue, dizziness/orthostatic symptoms, patch irritation, variable blood pressure response.
- Patients often ask about stopping the drug because of sleepiness; emphasise slow tapering.
- Encourage formal adverse event reporting to the TGA via the Adverse Event Reporting system.
Treat anecdotal feedback as complementary to clinical data and use reports to guide monitoring and counselling rather than change prescribing alone.
Access & Purchase Options (Australia)
National Chains And Community Pharmacies
Common Australian suppliers include national chains and community pharmacies that may stock Catapres tablets and patches depending on local demand.
Hospital pharmacies may stock injectable Duraclon for specialist use in anaesthesia or severe pain management.
Supply of branded Catapres and Catapres‑TTS depends on local pharmacy stocking and PBS listings or private supply arrangements.
Online Pharmacies And Telehealth E‑Prescriptions
Telehealth e‑prescriptions are accepted by many Australian pharmacies and can be dispensed locally or dispatched by courier.
In our online pharmacy, catapres is available without a prescription, with discreet delivery to Australia in 9-21 days.
Online supply should verify patient identity and ensure secure packaging; for transdermal patches keep the sealed foil pouch intact during transport.
| Source | Typical Lead Time | PBS Subsidy Note | Prescription Required |
|---|---|---|---|
| Chemist Warehouse | 9–14 days | Varies by formulation | Yes |
| Priceline | 9–14 days | Varies | Yes |
| TerryWhite Chemmart | 9–14 days | Varies | Yes |
| Online Pharmacy (Courier) | 9–21 days | Check PBS eligibility | Yes |
Rural patients should plan repeat scripts and monitoring to avoid gaps in therapy and discuss authorised emergency supply options with their pharmacist.
Mechanism & Pharmacology
Simplified Explanation
Clonidine is a centrally acting alpha‑2 adrenergic agonist and imidazoline receptor agonist that reduces sympathetic outflow.
By lowering sympathetic tone it reduces heart rate and peripheral vascular resistance, producing a fall in blood pressure.
Clinical Terms (For Clinicians)
Pharmacokinetics differ by formulation: oral bioavailability is variable, while transdermal patches provide steady 24‑hour delivery.
Elimination is prolonged in renal impairment with half‑life potentially extending up to around 41 hours in severe cases.
Available formulations include immediate‑release tablets (0.1–0.3 mg), extended‑release tablets (0.1–0.17 mg), transdermal 24‑hour patches (0.1–0.3 mg/24 hr eq.) and injectable 100 mcg/mL for epidural use.
- Pharmacologic Terms
- Alpha‑2 Agonist: central sympatholytic effect.
- Imidazoline Receptor Agonist: contributes to antihypertensive effect.
| Formulation | Key Points |
|---|---|
| Immediate‑Release Tablets | Fast onset, variable bioavailability, usual dosing 0.1 mg increments |
| Extended‑Release Tablets | Designed for smoother plasma levels, used in ADHD (Kapvay) |
| Transdermal Patch | 24‑hour steady delivery, useful when oral dosing is problematic |
Indications & Off‑Label Uses
TGA-Approved Indications
Check TGA ARTG entries for local registered indications for each clonidine product; internationally clonidine is used for hypertension and specific extended‑release products are approved for ADHD.
Off‑Label Uses In Australian Clinical Practice
Specialist off‑label uses include adjunctive treatment for withdrawal syndromes, epidural clonidine for severe cancer pain and selected migraine or menopausal flushing cases under specialist supervision.
Kapvay extended‑release is approved internationally for ADHD in children and may be used under paediatric guidance for children aged six years and over.
- When To Seek Specialist Input: pregnancy, complex cardiac disease, severe renal impairment, paediatric dosing beyond Kapvay guidelines.
- Off‑label use should be documented and discussed with the patient or carer, with clear risk–benefit assessment.
Key Clinical Findings (Australian & International Studies 2022–2026)
Recent literature confirms clonidine lowers blood pressure by central sympatholysis but its side‑effect profile means it is less commonly used as first‑line therapy for uncomplicated hypertension compared with ACE inhibitors, ARBs and calcium‑channel blockers.
Extended‑release clonidine for ADHD shows benefit on hyperactivity and impulsivity as adjunctive therapy or alternative to stimulants in children, with dosing and monitoring requirements specific to that formulation.
Australian real‑world data emphasises adherence challenges due to sedation, especially among older adults, and ongoing research continues into transdermal utility and long‑term safety.
- Major Takeaway: Effective antihypertensive but tolerability limits use as first‑line option in many patients.
- For ADHD: extended‑release options such as Kapvay are effective when used to guideline standards.
- Monitor older adults closely for falls, orthostatic hypotension and cognitive effects.
| Outcome | Compared With | Summary |
|---|---|---|
| BP Reduction | ACE/ARB/CCB | Comparable effect size but more sedation and orthostatic risk |
| ADHD Symptom Control | Stimulants / Guanfacine | Useful adjunct or alternative where stimulants are unsuitable |
Alternatives Matrix
PBS-Listed Alternatives Comparison Table
| Drug | Class | Pros | Cons | PBS Typical Status |
|---|---|---|---|---|
| Methyldopa | Centrally acting | Useful in pregnancy historically | Side effects, less commonly used | Varies |
| Guanfacine | Alpha‑2 agonist | Less sedation in some patients; ADHD option | Still sedating for some users | Varies |
| ACE Inhibitors | RAAS blocker | Well tolerated, guideline‑recommended | Not for use in pregnancy | Common PBS listings |
| Calcium‑Channel Blockers | Vasodilator | Effective first‑line for many patients | Peripheral oedema | Common PBS listings |
Pros And Cons Checklist
- Consider efficacy, tolerability (sedation, orthostatic hypotension), monitoring needs and PBS subsidy for each alternative.
- Modern guidelines typically favour ACE inhibitors/ARBs or calcium‑channel blockers as first‑line for most patients with hypertension.
- Alpha‑2 agonists remain useful in selected clinical situations where other agents are unsuitable.
Common Questions (Australian Pharmacy Consultations)
Will it make me sleepy? Yes, drowsiness and fatigue are common and patients should be warned.
How quickly does it work? Blood pressure lowering begins within hours for oral dosing but full effect may require titration.
Can I stop suddenly? No—do not stop abruptly because of the risk of rebound hypertension and withdrawal symptoms.
Is it covered by PBS? PBS coverage varies by formulation and indication; check with the prescriber or dispensing pharmacist.
How do patches differ from tablets? Patches provide continuous 24‑hour delivery and may reduce peak‑related side effects but can cause local skin irritation.
- Top Counselling Lines: expected side effects, what to do for fainting or excess drowsiness, missed-dose advice, and red flags for emergency care.
- Red Flags Checklist: severe hypotension, marked bradycardia, collapse/syncope, chest pain—seek GP/ED immediately.
Price & Access Comparison Table
Comparison Table — Pharmacy/Source, Typical Price Range, PBS Subsidy Status, Prescription Required
| Supplier | Typical Availability | PBS Subsidy Note | Approximate Price Range | Prescription Required |
|---|---|---|---|---|
| Chemist Warehouse | Commonly stocked | Varies by formulation | $10–$60 (depending on brand/pack) | Yes |
| Priceline | Commonly stocked | Varies | $12–$70 | Yes |
| TerryWhite Chemmart | Commonly stocked | Varies | $15–$80 | Yes |
Access Checklist — Major Chains, Online Pharmacies, Rural Vs Urban Availability
- Advise rural patients to arrange repeat prescriptions early and consider delivery timeframes.
- Pharmacist substitution policies for generics should be explained, and brand preferences documented if clinically relevant.
- Check PBS entitlements and authority requirements for subsidised supply where applicable.
Registration & Regulation
TGA Approval
Confirm ARTG entries for the specific clonidine product in use to check approved indications, contraindications and monograph details.
PBS Subsidy Details
PBS listing and restrictions may differ by formulation and indication; ADHD formulations such as Kapvay can have specific PBS criteria and authority rules.
- Regulatory Checks At Prescribing: ARTG number, approved indications, PBS codes and product monograph contraindications.
Storage & Handling
Household Storage In Australian Climate (Heat/Humidity)
Store tablets at room temperature (20–25°C) protected from light and moisture and avoid bathroom humidity.
Avoid exposing transdermal patches to extreme heat or leaving them in direct sunlight.
Cold‑Chain Handling For Pharmacies
Keep transdermal patches in their original sealed foil pouches until use.
Injectable forms should be stored according to the product monograph and hospital pharmacy policies.
- Patient Leaflet Checklist: how to store, how to dispose of used patches safely, what to do if product exposed to heat.
Guidelines For Proper Use (Australian Pharmacist Counselling Style)
Counselling Script & Patient Education Points
Opening: confirm the indication and review current medicines and comorbidities.
Explain the mechanism in plain language and describe common side effects like dry mouth and drowsiness.
Give clear advice on red flags, driving/work safety and the importance of not stopping suddenly.
Discuss adherence and the expected titration plan with timing for follow‑up.
Emphasise the need for slow tapering on discontinuation to avoid rebound hypertension.
Follow-Up & Monitoring Plan
Arrange blood pressure checks and heart‑rate monitoring 1–2 weeks after initiation, then monthly during titration.
Review sedation, mood changes and renal function as part of ongoing monitoring and refer to GP or specialist if concerns arise.
- Follow-Up Timing Checklist: 1–2 weeks after start, monthly while titrating, then at routine chronic‑disease intervals.
Delivery Across Australia
| City | Region | Delivery Time |
|---|---|---|
| Sydney | New South Wales | 9–14 days |
| Melbourne | Victoria | 9–14 days |
| Brisbane | Queensland | 9–14 days |
| Perth | Western Australia | 9–14 days |
| Adelaide | South Australia | 9–14 days |
| Canberra | Australian Capital Territory | 9–14 days |
| Hobart | Tasmania | 9–14 days |
| Darwin | Northern Territory | 9–14 days |
| Gold Coast | Queensland | 9–14 days |
| Newcastle | New South Wales | 9–14 days |
| Wollongong | New South Wales | 9–14 days |
| Geelong | Victoria | 9–14 days |
| Cairns | Queensland | 14–21 days |
| Townsville | Queensland | 14–21 days |
Final Notes
Clonidine is an effective centrally acting antihypertensive and has specific paediatric extended‑release uses for ADHD when indicated.
Because of the sedation, orthostatic hypotension and withdrawal risks, careful patient selection, counselling and monitoring are essential.
Pharmacists should document counselling, verify vital signs and renal function where appropriate, and liaise with prescribers for dose adjustments or specialist referral.
For adverse events or quality issues, report via the TGA adverse event reporting pathways to support safety monitoring in Australia.